Estrogen metabolite 2-methoxyestradiol prevents hypertension in deoxycorticosterone acetate-salt rats

Cardiovascular Drugs and Therapy

Volumn 27, Issue 1, 2013, Pages 17-22

  Yuan, Wensu ^a   Yu, Yueyi ^b   Li, Jingjing ^a   Singh, Pavneet ^b   Li, Dong ^a   Gui, Yu ^b   Zheng, Xi Long ^a,b  

^a NANKAI UNIVERSITY   (China)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

2 methoxyestradiol; Blood pressure; DOCA salt hypertensive rats

Indexed keywords

2 METHOXYESTRADIOL; DEOXYCORTICOSTERONE ACETATE; DIMETHYL SULFOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; HYPERTENSION; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THERAPY DELAY; TREATMENT RESPONSE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; DATA INTERPRETATION, STATISTICAL; DESOXYCORTICOSTERONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGENS; HYPERTENSION; RATS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873056774     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6428-7     Document Type: Article

References (21)

1. Gerhard M, Ganz P. How do we explain the clinical benefits of estrogen? From bedside to bench. Circulation. 1995;92(1):5-8.
2. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996;10(5):615-24.
3. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2004;286(2):R233-49.
4. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801-11.
5. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, et al. Effects of estrogen on the vascular injury response in estrogen receptor alpha, beta (double) knockout mice. Circ Res. 2001;89(6):534-9.
6. Dubey RK, Jackson EK, Keller PJ, Imthurn B, Rosselli M. Estradiol metabolites inhibit endothelin synthesis by an estrogen receptor-independent mechanism. Hypertension. 2001;37(2 Part 2):640-4.
7. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA. 1994;91(9):3964-8.
8. Gui Y, Zheng X-L. 2-methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells. Hypertension. 2006;47(2):271-80.
9. Gui Y, Zheng X-L, Zheng J, Walsh MP. Inhibition of rat aortic smooth muscle contraction by 2-methoxyestradiol. Am J Physiol Heart Circ Physiol. 2008;295(5):H1935-42.
10. Tofovic SP, Salah EM, Dubey RK, Melhem MF, Jackson EK. Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol. 2005;46(1):25-35.
11. Bonacasa B, Sanchez ML, Rodriguez F, Lopez B, Quesada T, Fenoy FJ, et al. 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. Maturitas. 2008;61(4):310-6.
12. Pinto YM, Paul M, Ganten D. Lessons from rat models of hypertension: from Goldblatt to genetic engineering. Cardiovasc Res. 1998;39(1):77-88.
13. Haasio K, Sopanen L, Vaalavirta L, Linden IB, Heinonen EH. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm. 2001;108(1):79-91.
14. Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany MJ. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension. 1993;21(4):391-7.
15. Watts SW, Rondelli C, Thakali K, Li X, Uhal B, Pervaiz MH, et al. Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 2007;292(5):H2438-H48.
16. Kirchner KA, Scanlon PH, Dzielak DJ, Hester RL. Endothelium-derived relaxing factor responses in Doca-salt hypertensive rats. Am J Physiol Heart Circ Physiol. 1993;265(3 Pt 2):R568-72.
17. Kanasaki K, Palmsten K, Sugimoto H, Ahmad S, Hamano Y, Xie L, et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia. Nature. 2008;453(7198):1117-21.
18. Lakhani NJ, Lepper ER, Sparreboom A, Dahut WL, Venitz J, Figg WD. Determination of 2-methoxyestradiol in human plasma, using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 2005;19(9):1176-82.
19. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol. 2005;4(6):366-70.
20. Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, et al. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Invest New Drugs. 2011;29(6):1465-74.
21. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res. 2005;11(18):6625-33.